Cover Image
市場調查報告書

生長抑制素第二型受體:開發平台分析

Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 359828
出版日期 內容資訊 英文 62 Pages
訂單完成後即時交付
價格
Back to Top
生長抑制素第二型受體:開發平台分析 Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Pipeline Review, H2 2016
出版日期: 2016年09月28日 內容資訊: 英文 62 Pages
簡介

本報告提供以生長抑制素第二型受體為標的的藥物適應症,開發階段,作用機制,給藥途徑及各分子類型分析,藥物的藥理作用之相關記述,並彙整迄今的研究開發趨勢,最新的新聞和發表,藥物的主要開發企業概要,休止/中止的計劃等資訊。

簡介

  • 調查範圍

生長抑制素第二型受體概要

治療藥的開發

生長抑制素第二型受體:開發中的產品 - 各開發階段

生長抑制素第二型受體:開發中的產品 - 治療範圍別

生長抑制素第二型受體:開發中的產品 - 各適應症

生長抑制素第二型受體:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

生長抑制素第二型受體:企業開發中的產品

生長抑制素第二型受體:大學/機關開發中的產品

生長抑制素第二型受體:治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

生長抑制素第二型受體的治療藥開發企業

  • Boehringer Ingelheim GmbH
  • Crinetics Pharmaceuticals, Inc.
  • Ipsen S.A.
  • OctreoPharm Sciences GmbH
  • Progenics Pharmaceuticals, Inc.
  • Sompharmaceuticals S.A.
  • Strongbridge Biopharma plc

藥物簡介

生長抑制素第二型受體:暫停中的計劃

生長抑制素第二型受體:開發中止的產品

生長抑制素第二型受體:主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0546TDB

Summary

Global Markets Direct's, 'Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Pipeline Review, H2 2016', provides in depth analysis on Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted pipeline therapeutics.

The report provides comprehensive information on the Somatostatin Receptor Type 2 (SRIF1 or SSTR2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Somatostatin Receptor Type 2 (SRIF1 or SSTR2)
  • The report reviews Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Somatostatin Receptor Type 2 (SRIF1 or SSTR2) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Somatostatin Receptor Type 2 (SRIF1 or SSTR2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Somatostatin Receptor Type 2 (SRIF1 or SSTR2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Somatostatin Receptor Type 2 (SRIF1 or SSTR2) Overview
  • Therapeutics Development
    • Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Products under Development by Stage of Development
    • Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Products under Development by Therapy Area
    • Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Products under Development by Indication
  • Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Products under Development by Companies
  • Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Products under Development by Universities/Institutes
  • Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Companies Involved in Therapeutics Development
    • Amryt Pharma plc
    • Boehringer Ingelheim GmbH
    • Crinetics Pharmaceuticals, Inc.
    • Ipsen S.A.
    • OctreoPharm Sciences GmbH
    • Progenics Pharmaceuticals, Inc.
    • Strongbridge Biopharma plc
  • Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Drug Profiles
    • AP-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • COR-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Edotreotide Labeled Yttrium 90 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FX-125L - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lanreotide acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OPS-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize SSTR2 and SSTR4 for Chronic Pain and Neuropathic Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Antagonize Somatostatin Receptor Type 2 for Neuroendocrine Tumors - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Dormant Projects
  • Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Discontinued Products
  • Somatostatin Receptor Type 2 (SRIF1 or SSTR2) - Featured News & Press Releases
    • Jul 27, 2016: Supplemental Application Filed for Somatuline in Japan for Additional Indication of Neuroendocrine Tumors
    • Jun 04, 2016: Endocrine Practice Publishes ELECT Phase III Trial Results in Adults with Carcinoid Syndrome
    • Jun 02, 2016: Ipsen Announces Data Presentations of Somatuline Depot (lanreotide) Injection in Gastroenteropancreatic Neuroendocrine Tumors at American Society of Clinical Oncology Annual Meeting
    • May 31, 2016: Strongbridge Biopharma plc Announces Presentation of COR-005 Data at the European Congress of Endocrinology
    • Oct 15, 2015: Ipsen Announces Eight Studies of Somatuline Depot (lanreotide) in Gastroenteropancreatic Neuroendocrine Tumors Being Presented at the North American Neuroendocrine Tumor Society Symposium
    • Oct 06, 2015: Health Canada Approves Somatuline Autogel (lanreotide) Injection for the treatment of enteropancreatic neuroendocrine tumors
    • May 14, 2015: Ipsen Announces Data Presentations for Somatuline Depot (lanreotide) in Gastroenteropancreatic Neuroendocrine Tumors at American Society of Clinical Oncology Annual Meeting
    • Apr 27, 2015: Crinetics Pharmaceuticals Awarded NIH Fast-Track Grant to Develop Somatostatin Receptor Agonist Drugs for Chronic Pain
    • Apr 14, 2015: MHRA approves Ipsen's Somatuline (lanreotide) Autogel 120mg as a new treatment for gastroenteropancreatic tumors
    • Jan 13, 2015: Ipsen Biopharmaceuticals to Present Further Data on Recently FDA-Approved Antitumor Therapy, Somatuline Depot (lanreotide), at Gastrointestinal Cancers Symposium
    • Dec 16, 2014: Ipsen's Somatuline Depot is the first therapy approved by the FDA in the United States for the treatment of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors
    • Nov 06, 2014: Ipsen Announces FDA Approval of a New Delivery Device for Somatuline Depot (lanreotide) Injection
    • Sep 01, 2014: Ipsen Announces Acceptance of Filings for Somatuline in the Treatment of GEP-NET1s in the US with Priority Review and in Europe
    • Jul 16, 2014: New England Journal of Medicine Publishes Ipsen's Somatuline CLARINET Phase III Results in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors
    • Jul 01, 2014: Ipsen submits marketing authorization applications in the US and Europe for Somatuline (lanreotide) in the treatment of gastroenteropancreatic neuroendocrine tumors
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Amryt Pharma plc, H2 2016
  • Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Pipeline by Crinetics Pharmaceuticals, Inc., H2 2016
  • Pipeline by Ipsen S.A., H2 2016
  • Pipeline by OctreoPharm Sciences GmbH, H2 2016
  • Pipeline by Progenics Pharmaceuticals, Inc., H2 2016
  • Pipeline by Strongbridge Biopharma plc, H2 2016
  • Dormant Projects, H2 2016
  • Dormant Projects (Contd..1), H2 2016
  • Dormant Projects (Contd..2), H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top